Amundi 13F: Adds $63M to AbbVie (ABBV) Stake
Amundi has boosted its position in AbbVie Inc. by 247,689 shares, raising its total to 10.7 million shares valued at approximately $2.7 billion.
Reviewed by automated data checks against the source filing. How we make and check alerts
Amundi added 247,689 shares to its stake in AbbVie Inc. ($ABBV), a 2.37% increase, according to a 13F filing with the SEC dated May 18, 2026. It reported 10,698,095 shares worth $2.70 billion at the end of the quarter.
Since the filing, $ABBV is up 1.8% after 1 week, up 5.7% after 1 month and up 38.1% to date (from the $206.66 close on May 18, 2026).
ABBV
AbbVie Inc.
Key Points
- Amundi increased its stake in AbbVie Inc. by 247,689 shares, bringing its total to 10,698,095 shares valued at about $2.7 billion as of May 18, 2026.
- AbbVie shares closed at $252.59 on the day of this filing, down from the previous close of $263.96, and are within a 52-week range of $190.75 to $267.47.
- Analysts have a consensus buy rating for AbbVie, with a mean price target of $278.61, reflecting continued confidence in the company's prospects.
Get $ABBV trade alerts by text
We text you when insiders, Congress or big funds trade $ABBV. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
Amundi Boosts Position in AbbVie
Amundi has increased its stake in AbbVie Inc. (NYSE: ABBV) by 247,689 shares, raising its total holdings to 10,698,095 shares. This boost represents a 2.37% increase in its position, valued at approximately $2.7 billion according to the latest Form 13F filing with the SEC, which reflects holdings as of May 18, 2026.
Institutional Activity Around AbbVie
No other funds reported changes in their AbbVie positions in the latest filings, so Amundi's move stands out among institutional investors. Recent activity from other funds has shown a mix of trimming and maintaining stakes in AbbVie, highlighting a cautious sentiment in the market.
Stock Performance and Current Price
AbbVie shares traded at $252.59 on the day this article is published, down from the previous close of $263.96. The stock is currently within a 52-week range of $190.75 to $267.47, which indicates it has been fluctuating but remains well above its 52-week low. This increase in Amundi's stake comes at a time when the stock has shown some volatility, potentially reflecting confidence in the company’s long-term growth.
Analysts Set New Price Targets
On October 13, 2026, RBC Capital reiterated its Outperform rating on AbbVie with a price target of $280. UBS maintained a Neutral rating with a target of $275 on October 9, 2026, while Guggenheim reiterated a Buy rating with a target of $288 on the same day. JP Morgan and Cantor Fitzgerald also maintained Overweight ratings, with targets of $300 and $290, respectively. The consensus among analysts is a buy recommendation with a mean price target of $278.61, suggesting that analysts remain optimistic about AbbVie's future performance.
What AbbVie Inc. Does
AbbVie Inc., based in North Chicago, Illinois, focuses on researching and developing a range of medicines and therapies, including treatments for autoimmune diseases, cancers, and chronic conditions. The company's diverse portfolio includes well-known products like Skyrizi and Imbruvica, which contribute to its strong market presence.
What’s Next for AbbVie
AbbVie is set to report its next earnings on October 29, 2026. As a reminder, the latest 13F filing reflects Amundi’s holdings as of the end of the reporting period and may not represent its current position. Investors will be watching closely for further updates and any changes in institutional sentiment following the upcoming earnings report.
Related Filing Alerts
Source: Amundi's 13F filing on $ABBV (May 18, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Amundi 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts